DelveInsight’s ‘Major Depressive Disorder Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Major Depressive Disorder therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Major Depressive Disorder pipeline domain.
Key Takeaways from the Major Depressive Disorder Pipeline Report
- Over 75+ Major Depressive Disorder pipeline therapies are in various stages of development, and their anticipated acceptance in the Major Depressive Disorder market would significantly increase market revenue.
- Leading Major Depressive Disorder companies developing novel drug candidates to improve the Major Depressive Disorder treatment landscape include Sage Therapeutics, Relmada Therapeutics, Inc, Minerva Sciences, Sirtsei Pharmaceuticals, Inc., Small Pharma, BioLite Inc, and others.
- Promising Major Depressive Disorder pipeline therapies in various stages of development include SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421, and others.
Major Depressive Disorder Overview
Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of MDD isn’t known.
However, there are several factors that can increase the risk of developing the condition. Symptoms must occur for a period of 2 or more weeks and at least one symptom is either depressed mood or loss of interest or pleasure. MDD is often treated with medication and psychotherapy. Some lifestyle adjustments can also help ease certain symptoms.
Request for a sample page report to know more about major depressive disorder treatment algorithm and diagnosis.
Major Depressive Disorder Pipeline Analysis: Drug Profile
REL-1017: Relmada Therapeutics, Inc
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD.
Discover more about the emerging Major Depressive Disorder drugs @ Major Depressive Disorder Treatment Drugs
Major Depressive Disorder Key Companies
- Sage Therapeutics
- Relmada Therapeutics, Inc
- Minerva Sciences
- Sirtsei Pharmaceuticals, Inc.
- Small Pharma
- BioLite Inc
- And others
Major Depressive Disorder Pipeline Therapies
- SAGE-217
- REL-1017
- Seltorexant
- SP-624
- SPL026
- PDC-1421
- And others.
Major Depressive Disorder Pipeline Therapeutics Assessment
- By development stage
- By product type
- By route of administration
- By molecule type
- By MOA type
Scope of the Major Depressive Disorder Pipeline Report
- Coverage: Global
- Key Major Depressive Disorder Companies: Sage Therapeutics, Relmada Therapeutics, Inc, Minerva Sciences, Sirtsei Pharmaceuticals, Inc., Small Pharma, BioLite Inc, and others
- Key Major Depressive Disorder Pipeline Therapies: SAGE-217, REL-1017, Seltorexant, SP-624, SPL026, PDC-1421, and others
Find out more about the Major Depressive Disorder treatment options in development @ Major Depressive Disorder Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Other Trending Reports:
- Asthma Diagnostic Devices Market
- Chronic Obstructive Pulmonary Disease Treatment Devices Market
- Airway Management Devices Market
- Cough Assist Devices Market
- Pulse Oximeters Market
- Hemodialysis
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Kritika Rehani
info@delveinsight.com
+1(919)321-6187
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/